Anti-LUZP2/ KFSP2566/ PRO6246 functional antibody

Anti-LUZP2/ KFSP2566/ PRO6246 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to LUZP2/LUZP2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0591-Ab-1/ GM-Tg-hg-SE0591-Ab-2Anti-Human LUZP2 monoclonal antibodyHuman
GM-Tg-rg-SE0591-Ab-1/ GM-Tg-rg-SE0591-Ab-2Anti-Rat LUZP2 monoclonal antibodyRat
GM-Tg-mg-SE0591-Ab-1/ GM-Tg-mg-SE0591-Ab-2Anti-Mouse LUZP2 monoclonal antibodyMouse
GM-Tg-cynog-SE0591-Ab-1/ GM-Tg-cynog-SE0591-Ab-2Anti-Cynomolgus/ Rhesus macaque LUZP2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0591-Ab-1/ GM-Tg-felg-SE0591-Ab-2Anti-Feline LUZP2 monoclonal antibodyFeline
GM-Tg-cang-SE0591-Ab-1/ GM-Tg-cang-SE0591-Ab-2Anti-Canine LUZP2 monoclonal antibodyCanine
GM-Tg-bovg-SE0591-Ab-1/ GM-Tg-bovg-SE0591-Ab-2Anti-Bovine LUZP2 monoclonal antibodyBovine
GM-Tg-equg-SE0591-Ab-1/ GM-Tg-equg-SE0591-Ab-2Anti-Equine LUZP2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0591-Ab-1/ GM-Tg-hg-SE0591-Ab-2; GM-Tg-rg-SE0591-Ab-1/ GM-Tg-rg-SE0591-Ab-2;
GM-Tg-mg-SE0591-Ab-1/ GM-Tg-mg-SE0591-Ab-2; GM-Tg-cynog-SE0591-Ab-1/ GM-Tg-cynog-SE0591-Ab-2;
GM-Tg-felg-SE0591-Ab-1/ GM-Tg-felg-SE0591-Ab-2; GM-Tg-cang-SE0591-Ab-1/ GM-Tg-cang-SE0591-Ab-2;
GM-Tg-bovg-SE0591-Ab-1/ GM-Tg-bovg-SE0591-Ab-2; GM-Tg-equg-SE0591-Ab-1/ GM-Tg-equg-SE0591-Ab-2
Products NameAnti-LUZP2 monoclonal antibody
Formatmab
Target NameLUZP2
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LUZP2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0591-Ag-1Recombinant multi-species LUZP2/ KFSP2566/ PRO6246 protein


    Target information

    Target IDGM-SE0591
    Target NameLUZP2
    Gene ID338645,233271,100910839,702894,612193,101100082,785165
    Gene Symbol and Synonyms9330154K17Rik,D130073E01,KFSP2566,LUZP2,PRO6246,RGD1563838
    Uniprot AccessionQ86TE4
    Uniprot Entry NameLUZP2_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000187398
    Target ClassificationN/A

    The target: LUZP2, gene name: LUZP2, also named as KFSP2566, PRO6246. This gene encodes a leucine zipper protein. This protein is deleted in some patients with Wilms tumor-Aniridia-Genitourinary anomalies-mental Retardation (WAGR) syndrome. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Oct 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.